# A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before

> **NCT04587427** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1067 (actual)

## Conditions studied

- Bone Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Radium 223 dichloride (Xofigo, BAY88-8223)

## Key facts

- **NCT ID:** NCT04587427
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-15
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 1067 (ACTUAL)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04587427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04587427, "A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04587427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*